Valuation: AstraZeneca Pharma India Limited

Market Cap 19TCr 201.32Cr 175.97Cr 162.74Cr 149.33Cr 282.63Cr 287.54Cr 1.94TCr 762.4Cr 9.47TCr 756.02Cr 739.41Cr 33TCr P/E 2024
82.4x
P/E 2025 186x
Enterprise Value 19TCr 196.12Cr 171.43Cr 158.54Cr 145.48Cr 275.34Cr 280.12Cr 1.89TCr 742.74Cr 9.23TCr 736.52Cr 720.34Cr 32TCr EV / Sales 2024
9.88x
EV / Sales 2025 12.2x
Free-Float
18.42%
Yield 2024
0.45%
Yield 2025 0.37%
1 day-1.77%
1 week-0.71%
Current month-1.51%
1 month-3.95%
3 months-5.55%
6 months-2.36%
Current year-10.19%
1 week 7,945
Extreme 7945
8,399
1 month 7,945
Extreme 7945
8,766.35
Current year 7,630
Extreme 7630
9,219.25
1 year 7,630
Extreme 7630
9,850
3 years 3,715.05
Extreme 3715.05
10,653.05
5 years 2,437.75
Extreme 2437.75
10,653.05
10 years 882.55
Extreme 882.55
10,653.05
Manager TitleAgeSince
Chief Executive Officer - 01/07/2025
Director of Finance/CFO - 01/10/2023
Chief Tech/Sci/R&D Officer - 03/03/2025
Director TitleAgeSince
Director/Board Member 67 02/12/2016
Chairman 52 30/09/2024
Director/Board Member 67 25/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
-1.77%-0.71%-11.70%+115.62% 214.02Cr
+1.08%-3.93%+48.03%+161.48% 1,03100Cr
+1.19%-3.52%+51.70%+57.14% 59TCr
+4.21%+1.79%+33.48%+88.67% 43TCr
+0.42%-0.99%+30.04%+22.27% 33TCr
+1.03%-2.10%+28.32%+45.08% 28TCr
+0.49%-11.32%+20.31%+22.32% 26TCr
+1.59%+3.91%-22.47%-36.84% 22TCr
+3.70%+2.19%+24.27%+63.09% 19TCr
+3.49%+1.08%+24.08%+75.92% 16TCr
Average +1.31%-3.31%+22.61%+61.47% 35.06TCr
Weighted average by Cap. +1.57%-4.30%+34.59%+80.14%

Financials

2024 2025
Net sales 1.3TCr 13Cr 12Cr 11Cr 9.97Cr 19Cr 19Cr 129.61Cr 51Cr 632.65Cr 50Cr 49Cr 2.18TCr 1.72TCr 18Cr 16Cr 14Cr 13Cr 25Cr 25Cr 171.71Cr 67Cr 838.12Cr 67Cr 65Cr 2.89TCr
Net income 161.51Cr 1.68Cr 1.47Cr 1.35Cr 1.24Cr 2.35Cr 2.39Cr 16Cr 6.35Cr 79Cr 6.29Cr 6.16Cr 272.29Cr 115.74Cr 1.2Cr 1.05Cr 97.1L 89.1L 1.69Cr 1.72Cr 12Cr 4.55Cr 57Cr 4.51Cr 4.41Cr 195.13Cr
Net Debt -500.98Cr -5.2Cr -4.54Cr -4.2Cr -3.86Cr -7.3Cr -7.43Cr -50Cr -20Cr -244.64Cr -20Cr -19Cr -844.62Cr -500.41Cr -5.19Cr -4.54Cr -4.2Cr -3.85Cr -7.29Cr -7.42Cr -50Cr -20Cr -244.37Cr -20Cr -19Cr -843.66Cr
Logo AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Employees
600
Date Price Change Volume
16/26/16 8,092.00 -1.77% 737
15/26/15 ₹8,237.40 +0.64% 273
14/26/14 ₹8,185.10 -1.04% 227
13/26/13 ₹8,271.35 +1.82% 2,246
10/26/10 ₹8,123.85 +0.15% 185
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. ASTRAZEN Stock